A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback